Premium
Lidamidine's effects on the lower gastrointestinal tract: A review
Author(s) -
DiJoseph John F.,
Mir G. Nabi
Publication year - 1986
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430070202
Subject(s) - gastrointestinal tract , diarrhea , intestinal motility , potency , medicine , alpha (finance) , drug , pharmacology , motility , in vitro , chemistry , biology , surgery , genetics , construct validity , patient satisfaction , biochemistry
Lidamidine is a new, nonnarcotic, nonanticholinergic drug intended for the treatment of diarrhea. In preclinical test models, it compares favorably in both potency and duration of action with marketed antidiarrheal drugs. Lidamidine's intestinal antisecretory effects are mediated through the activation of peripheral alpha‐2 adrenoceptors. Lidamidine crosses the blood brain barrier poorly and is therefore devoid of the centrally mediated alpha‐2 effects that have limited the use of other alpha‐2 adrenoceptor agonists in the intestinal tract. Lidamidine relaxes circular and longitudinal smooth muscle in the intestinal tract and may be useful for treatment of certain intestinal motility disorders. In clinical trials, lidamidine has proven to be effective for the management of diarrheal diseases.